Page 2 of 3 · 68 questions tagged cardiovascular.
I have three numbers on my report that all claim to measure roughly the same risk and they do not agree about how I am doing. LDL-C 2.6 mmol/L, which is described in…
I have three data points across nine months, which I hope is enough to see a trend. I would rather understand the derivation than memorise the outcome. Two people I…
The particulars: PIONEER-4 · oral semaglutide. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…
I would like to know how much of this is established and how much is a reasonable story. I suspect the usual explanation for this is wrong, or at least incomplete. I…
I have the full paper rather than the abstract, and the supplementary appendix. I would rather understand the derivation than memorise the outcome. Two people I asked…
I have the full paper rather than the abstract, and the supplementary appendix. I would rather understand the derivation than memorise the outcome. Two people I asked…
What I am working with: PIONEER-1 · oral semaglutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
What I have: SURMOUNT-5 · tirzepatide. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
I have three data points across nine months, which I hope is enough to see a trend. This should be a straightforward calculation and I keep getting two different…
Concretely: STEP 4 · semaglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which…
This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I want to know whether this is a real physical effect or…
What I am working with: SURMOUNT-OSA · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the…
The case in front of me: STEP 1 · semaglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
I have the full paper rather than the abstract, and the supplementary appendix. I am at the decision point and I would rather think it through than improvise. I would…
The case in front of me: STEP 5 · semaglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…
SOUL tested oral semaglutide 14 mg daily in people with type 2 diabetes and either atherosclerotic cardiovascular disease or chronic kidney disease, and reported a…
I am reading the trial table rather than the press release, which is why the numbers differ. I would like the arithmetic checked rather than the conclusion asserted.…
Stated plainly: TRIUMPH-1 · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
I have three data points across nine months, which I hope is enough to see a trend. I can do the algebra. I am not confident about the conversion factors. If there is…
My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. Please show the division. I want to check my own against yours. I…
This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I have worked this out and I would like someone to find…
What I am working with: SOUL · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the full…
Setup, so nobody has to ask: TRIUMPH-1 · retatrutide. I have read the primary source rather than the summary, which has left me with more questions. I understand the…
What I am working with: SURPASS-3 · tirzepatide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…